EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Regurgitant volume to LA volume ratio in patients with secondary MR: the COAPT trial

Augustin Coisne iD, Andrea Scotti iD, Juan F Granada, Paul A Grayburn, Michael J Mack, David J Cohen, Saibal Kar iD, D Scott Lim, JoAnn Lindenfeld iD, Jeroen Bax, Lak N Kotinkaduwa, Björn Redfors und 3 weitere

European Heart Journal - Cardiovascular Imaging · 2024

DOI: 10.1093/ehjci/jead328 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Imaging, 2024. Verfasst von Augustin Coisne und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Abbott.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The conceptual framework of proportionate vs. disproportionate mitral regurgitation (MR) translates poorly to individual patients with heart failure (HF) and secondary MR. A novel index, the ratio of MR severity to left atrial volume (LAV), may identify patients with ‘disproportionate’ MR and a higher risk of events. The objectives, therefore, were to investigate the prognostic impact of MR severity to LAV ratio on outcomes among HF patients with severe secondary MR randomized to transcatheter edge-to-edge repair (TEER) with the MitraClip™ device plus guideline-directed medical therapy (GDMT) vs. GDMT alone in the COAPT trial. Methods and results The ratio of pre-procedural regurgitant volume (RVol) to LAV was calculated from baseline transthoracic echocardiograms. The primary endpoint was 2-year covariate-adjusted rate of HF hospitalization (HFH). Among 567 patients, the median RVol/LAV was 0.67 (interquartile range 0.48–0.91). In patients randomized to GDMT alone, lower RVol/LAV was independently associated with an increased 2-year risk of HFH (adjHR: 1.77; 95% CI: 1.20–2.63). RVol/LAV was a stronger predictor of adverse outcomes than RVol or LAV alone. Treatment with TEER plus GDMT compared with GDMT alone was associated with lower 2-year rates of HFH both in patients with low and high RVol/LAV (Pinteraction = 0.28). Baseline RVol/LAV ratio was unrelated to 2-year mortality, health status, or functional capacity in either treatment group.

Conclusion

Low RVol/LAV ratio was an independent predictor of 2-year HFH in HF patients with severe MR treated with GDMT alone in the COAPT trial. TEER improved outcomes regardless of baseline RVol/LAV ratio. Clinical Trial Registration Trial Name: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) (COAPT) ClinicalTrial.gov Identifier NCT01626079 URL https://clinicaltrials.gov/ct2/show/NCT01626079

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHumansFemaleMaleAgedSeverity of Illness IndexEchocardiographyHeart FailurePrognosisRisk AssessmentHeart AtriaTreatment OutcomeCardiac CatheterizationAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

COAPTleft atrial volumemitral regurgitationregurgitant volumetranscatheter edge-to-edge repair

Autor:innen und Institutionen

  • Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA.
  • Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
  • University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France.
  • Department of Internal Medicine, Division of Cardiology, Baylor Scott & White Heart and Vascular Hospitals, Plano, TX, USA.
  • Baylor Scott & White Health, Plano, TX, USA.
  • Saint Francis Hospital, Roslyn, NY, USA.

ORCID-Profile: Augustin Coisne, Andrea Scotti, Saibal Kar, JoAnn Lindenfeld, Gregg W Stone

Förderung

  • Abbott

Zitieren

APA

Coisne, A., Scotti, A., Granada, J. F., Grayburn, P. A., Mack, M. J., Cohen, D. J., Kar, S., Lim, D. S., Lindenfeld, J., Bax, J., Kotinkaduwa, L. N., Redfors, B., Weissman, N. J., Asch, F. M., & Stone, G. W. (2024). Regurgitant volume to LA volume ratio in patients with secondary MR: the COAPT trial. European Heart Journal - Cardiovascular Imaging. https://doi.org/10.1093/ehjci/jead328

Vancouver

Coisne A, Scotti A, Granada JF, Grayburn PA, Mack MJ, Cohen DJ, et al. Regurgitant volume to LA volume ratio in patients with secondary MR: the COAPT trial. European Heart Journal - Cardiovascular Imaging. 2024. doi:10.1093/ehjci/jead328

BibTeX
@article{Coisne2024,
  author = {Coisne, Augustin and Scotti, Andrea and Granada, Juan F and Grayburn, Paul A and Mack, Michael J and Cohen, David J and Kar, Saibal and Lim, D Scott and Lindenfeld, JoAnn and Bax, Jeroen and Kotinkaduwa, Lak N and Redfors, Björn and Weissman, Neil J and Asch, Federico M and Stone, Gregg W},
  title = {Regurgitant volume to LA volume ratio in patients with secondary MR: the COAPT trial},
  journal = {European Heart Journal - Cardiovascular Imaging},
  year = {2024},
  doi = {10.1093/ehjci/jead328}
}
Kostenlos starten →